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Hypertension is the major risk factor for cardiovascular diseases and stroke and it is one of leading causes of disability 
and mortality worldwide. The present study was aimed to investigate the antihypertensive and vasodilation properties of 
chrysin, a naturally occurring flavone, in hypertensive rats. Hypertension was induced using Nω-nitro-l arginine methyl ester 
(L-NAME; 40 mg/kg BWT/day for 4 weeks) in adult rats and chrysin (25 mg/kg BWT/day) or vehicle was administered for 
4 weeks. A siginificant increase of blood pressure and serum fibrinogen along with a significant reduction of bilirubin level 
were observed in hypertensive rats and these changes were significantly attenuated upon administration of crysin. Further, 
L-NAME induced increase of tissue levels of mRNAs of β-MHC and TGF-β (in heart) as well as eNOS (in aorta, heart, 
kidney) were significantly reduced in chrysin treated rats. These results suggest that chrysin has a potential to attenuate 
impairment of organs (heart and renal) and endothelial function caused by L-NAME induced hypertension. 
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Hypertension is one of the most important factors 
associated with development of several diseases such 
as heart failure, renal failure, coronary heart disease, 
atherosclerosis, myocardial infarction and stroke. 
Endothelial dysfunction, which results from nitric 
oxide (NO) deficiency, is one of the causes of 
essential hypertension
1
. Worldwide, hyper-tension is 
estimated to cause 7.1 million premature deaths per 
year and its prevalence in developing countries is 
already as high as those in developed countries
2
. 
Nitric oxide (NO) is one of the smallest biologically 
active molecules that are produced from L-arginine by 
nitric oxide synthase (NOS). There are three iso forms 
of the nitric oxide synthase: neuronal (nNOS), 
inducible (iNOS) and endothelial (eNOS)
3
. Chronic 
inhibition of NO synthesis by the administration of  
L-NAME (N
ω
-nitro-L arginine methyl ester) inhibits 
NOS activity and hence NO biosynthesis, leading to 
hypertension, atherosclerosis and cardiac remodeling
4
, 
an impairment of endothelial dependent relaxation and 
renal function alteration
5
. Experimental models of 
hypertension have been associated with reduced serum 
and tissue level of magnesium (Mg), the second most 
abundant intracellular cation
6
. Mg is known to be 
essential for enzymatic activity, structural stability of 
anions such as nucleotides, and maintaining body 
physiology. Mg affects the electrical properties of 
membranes and their permeability characteristics
7
. 
Plant polyphenolic compounds the flavanoids 
consist of number of classes, as flavanols, flavones and 
flavans. A naturally occurring flavones, Chrysin (5, 7-
dihydroxy flavones structure shown in Fig. 1) 
contained in flowers blue passion flower (Passiflora 
caerulea), Indian trumpet flower, as well as in edible of 
mushrooms
8
, honey and propolis
9
. At the same time it 
possess antioxidant capacity, anti-inflammatory activity, 





. Chrysin having tyrosinase 
inhibitory activity, moderate aromatase inhibitory 
activity, and another important role are inhibits 
estradiol-induced DNA synthesis. C-iso-prenylated 
hydrophobic derivatives of chrysin are potential  
P-glycoprotein modulators in tumour cells
12
. The 
earlier study showed that chrysin has antihypertensive 
effects, and reduces hepatic, renal damages and 
endothelial dysfunction in L-NAME induced 
hypertensive rats
13
. The present study aimed to evaluate 
the effect of chrysin on blood pressure, detection of 
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mRNA expression of β-MHC and TGF-β, measurement 
of Mg levels in Plasma and fibrinogen, bilirubin and 
albumin in serum in the L-NAME induced hypertensive 
rats against the control and unsupplemented groups. 
 
Materials and Methods 
Chemicals 
Chrysin and L-NAME was purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). All other 
chemicals used in this study were of analytical grade and 
obtained from E-Merck or HIMEDIA, Mumbai, India. 
 
Animals 
All the animal handling and experimental procedures 
were approved by the Institutional Animal Ethics 
Committee of Bharathidasan University and animals 
were cared for in accordance with the Indian National 
Law on Animal Care and Use. Male Wistar rats  
(180-220 g) were purchased from the Indian Institute of 
Science, Bangalore, India. Rats were housed in plastic 
cages with filter tops under controlled conditions of a  
12 h light-dark cycle, 50% humidity and temperature of 
28C. All rats received a standard pellet diet (Lipton 
Lever Mumbai, India) and water ad libitum. 
 
Induction of L-NAME induced hypertension 
L-NAME (40 mg/kg B.W) was dissolved in 
drinking water and given to rats at an interval of 24 h 
for 8 weeks. Mean arterial blood pressure (MAP) was 
measured using tail cuff method. MAP measurements 




Blood pressure measurements 
Systolic and diastolic blood pressures were 
determined by the tail-cuff method (IITC, model 31, 
Woodland Hills, CA, USA). The animals were placed 
in a heated chamber at an ambient temperature of  
30-34°C for 15 min and from each animal one to nine 
blood pressure values were recorded. The lowest three 
readings were averaged to obtain a mean blood 
pressure. All recordings and data analyses were done 
using a computerized data acquisition system and 
software. 
Study design 
Animals were divided into four groups of six rats 
each and all were fed the standard pellet diet. The rats 
were grouped as given below. 
 
Group I Control 




Group III L-NAME induced hypertension (40 mg/kg 
of B.W) 
Group IV L-NAME induced hypertension (40 mg/kg 
of B.W) + Chrysin (25 mg/kg of B.W) 
 
Administered orally once in a day in the morning 
for 4 weeks. The compound was suspended in 2% 
dimethyl sulfoxide solution and fed group I and III by 
intubation. After 8 weeks morning, the animals were 
sacrificed by cervical dislocation. The blood was 
collected in clean dry test tubes and allowed to 
coagulate at ambient temperature for 30 min. Serum 
was separated by centrifugation at 2000 rpm for  
10 min. The blood, collected in a heparinized 
centrifuge tube, was centrifuged at 2000 rpm for  
10 min and the plasma separated was removed by 
aspiration and was used for estimations. 
The Liver, Brain and kidney were immediately 
removed and washed in ice-cold saline to remove the 
blood. The tissues were sliced and homogenized in 
0.1 M Tris-HCl buffer (pH 7.0). The homogenates 
were centrifuged at 48 × g for 10 min at 4C in a cold 
centrifuge. The supernatants were separated and used 







 and serum 
bilirubin
17
 were measured. 
 
Real-time polymerase chain reaction 
Single-strand cDNA was reverse transcribed using a 
First Strand cDNA Synthesis Kit (Amersham 
Biosciences, Buckinghamshire, UK) and gene-specific 
antisense primers (the Centre for Genomic Application, 
New Delhi, India). Primers for real-time reverse 
transcription polymerase chain reaction (RT-PCR) 
were designed for eNOS and cyclophilin A using 
Primer Express™ Software (PerkinElmer Inc., 
Waltham, MA, USA) and are listed in (Table 1). Real-
time RT-PCR reactions were performed using SYBR 
Green PCR Master Mix (Thermo Fisher Scientific) on 
ABI Prism 7300 Sequence Detection System (Thermo 
Fisher Scientific). For each 25 μL of PCR reaction, 
1.0 μL of cDNA, 1.0 μL of sense and antisense 
primers (2.5 μM each), 12.5 μL of SYBR Green PCR 
 
 
Fig. 1 — Chemical structure of chrysin (5,7 dihydroxyflavone) 




Master Mix, and 10.5 μL of PCR grade water were 
used. The cycling conditions were 94°C for 10 min, 
followed by 40 cycles of 94°C for 15 sec and 59°C for 
30 sec. The PCR reactions were performed in five 
replicates for each gene. Relative transcript quantity was 
calculated using the ΔΔCt method, with cyclophilin A as 
the endogenous reference gene amplified from the 
samples. A validation experiment for ΔΔCt calculation 
was performed for each target by plotting the ΔCt  
(Ct target – Ct reference) values versus log input 
amounts to create a semilog regression line. The  
slope of the resulting semilog regression line was  
used as a general criterion for the validation 
experiment. The absolute value of the slope was < 0.1. 
Finally, the amount of target (drug treatment) 
normalized to the endogenous reference and relative  






Statistical analysis were analysed by one-way 
analysis of variance (ANOVA) followed by Duncan’s 
multiple range test (DMRT) using a commercially 
available Software Package for the Social Science 
(SPSS) software package version 11.0. Results were 
expressed as mean ± SD for six rats in each group. 




Chrysin (25 mg/kg of B.W) dose was taken for this 
study based on previous our studies. Table 2 shows 
the levels of fibrinogen, albumin and serum bilirubin 
in L-NAME hypertensive rats before and after 
treatment with chrysin and in normotensives.  
L-NAME induced hypertensive rats had an elevated 
level of fibrinogen and a lowered level of serum 
bilirubin when compared to normotensives. There was 
no significant difference observed in the levels of 
albumin. A significant decrease in plasma fibrinogen 
level and increase in serum bilirubin levels were 
observed after chrysin consumption. We did not 
receive any reports on or find any adverse effects on 
the experimental animals either during or after the 
treatment period of group I and II. 
Table 3 shows L-NAME rat hearts showed 
significantly (P <0.05) elevated mRNA expression of 
TGF-β and β-MHC, compared with control. chrysin 
treatment significantly (P <0.05) suppressed the 
expression of above mRNAs in the L-NAME rat 
heart. But there is no significant difference between 
group I and II.  
 
eNOS mRNA expression studies 
eNOS mRNA expression (Fig. 2) was studied in 
aorta, heart, and kidney using cyclophilin A as the 
internal standard. During the treatment with l-NAME, 
eNOS mRNA expression decreased significantly in  
all the three organs, whereas it increased during  
the treatment with chrysin in L-NAME-induced 
hypertensive rats with chrysin showing better results in 
the kidney. In the kidney, no significant difference was 
observed between the mRNA levels of chrysin and the 
control group. There is no significant difference between 
group I and II. 
There are no changes between group I and II. 
Chrysin (25 mg/kg of B.W) is an effective dose for all 
parameters significant effect in L-NAME induced rats 
as compared to control rats. Chrysin in normal rats 
didn’t show any significant. 
Table 1 — Details of primers used for real-time RT-PCR 
Gene  Primer sequence 
TGF-β Forward primer: 5′-ATG ACA TGA ACC 
GAC CCT TC-3 
Reverse primer : 5′-GTA GTT GGT ATC 
CAG GGC TCT C-3′ 
β-MHC Forward primer: 5′-GTA GAC AAG GGC 
AAA GGC AA-3′ 
Reverse primer : 5′-GGA TGA TGC AGC 
GTA CAA AG-3′ 




Notes: Primers were designed by Primer Express™ Software  
and were synthesized at The Centre for Genomic Application, 
New Delhi, India. 
Table 2 — Effect of chrysin on fibrinogen, bilirubin and albumin in serum of control and L-NAME induced hypertensive rats 
 Control Control+25 mg chysin L-NAME induced hypertension L-NAME+25 mg chrysin 
Fibrinogen (mg/dL) 216.02 ± 14.48 a 215.95 ± 13.62 a 327.85± 19.39 b 219.72 ± 15.27 c 
Bilirubin(mg/dL) 0.95 ± 0. 19a 0.96 ± 0. 08 a 0.72 ± 0.06 b 0.94 ± 0.07c 
Albumin (mg/dL) 4.82 ± 0.08a 4.83 ± 0.05 a 4.70 ± 0.04 b 4.09 ± 0.07c 
Each value is mean ± S.D. for six rats in each group. 
Values not sharing a common superscripts (a, b and c) differ significantly at P < 0.05 (DMRT). 





Numerous cross-sectional epidemiologic studies
18
 
have reported a modest positive association between 
plasma fibrinogen levels and blood pressure. Perhaps 
augmented synthesis of fibrinogen may be due to 
increased utilization during mechanical injury caused by 
L-NAME hypertension. Some experimental evidence 
suggests that administering pharmacologic agents to 
lower blood pressure can reduce fibrinogen levels or 
blood viscosity
19
; this also implies that high blood 
pressure may raise hemorrheologic parameters, rather 
than vice versa. Plasma fibrinogen concentration 
depends on the rate at which it is secreted into the 
blood from the liver where it is synthesized and on  
the rate of its elimination from the blood. This is 
either through the removal of intact fibrinogen by 
different organs; by its degradation in the blood to 
soluble products; or by conversion into and deposition 
as insoluble fibrin
20
. A significant reduction in 
fibrinogen level was observed in patients with 
hypertension after chrysin supplementation. Probably, 
chrysin may facilitate uptake and degradation of  
plasma fibrinogen by the organs, thereby decreasing the 
plasma fibrinogen. 
Bilirubin, a bile pigment, acts as a potent 
physiologic antioxidant that may provide important 
protection against coronary artery disease
21
. The 
lower serum bilirubin levels in the untreated  
L-NAME induced hypertensive rats to support the 
evidence of increased oxidant load in these rats
22
. The 
significant increase of serum bilirubin level in  
the supplementation with the increased antioxidants 
level we reported patients with L-NAME induced 
hypertensive rats in our study was compatible 
previously
23
, from the chrysin. The plasma albumin 
concentration is a result of its rates of synthesis and 
degradation/excretion and its distribution between 
intra- and extravascular compartments
24
. There was 
no significant difference observed in the level of 
albumin in all groups. 
NO, essential for the proper functioning of 
cardiovascular system, is derived from L-arginine  
by NO synthase in endothelial cells. NO synthase 
inhibition produces hypertension, endothelial damage, 
cardiachypertrophy, inflammation, atherosclerosis, 
ventricular contractile dysfunction, and fibrosis
25
. 
Chronic inhibition of NOS by L-NAME caused an 
increase of blood pressure associated with vascular 
structural change. It has been shown that the ventricular 
hypertrophyin in L-NAME model of hypertension is 
linked to an increase of fibrosis and left ventricle 
hypertrophy.  
Decreased functional activity of NOS in the long-
term L-NAME-treated rats is well established. chrysin 
almost homogeneously increased the levels of eNOS 
mRNA expression in the tissues of the L-NAME-
induced hypertension model, which was contradictory 
to the effect of L-NAME. These findings are in good 
agreement with the previously reported ACE 
inhibitors
26
. Additionally, our present findings were 
also validated by the potency standard compound 
chrysin to restore eNOS mRNA expression in rat 
aorta, heart, and kidney with the effect being more 
prominent in kidney tissues.  
We found that treatment with chrysin augmented 
eNOS expression. Such an increase in the expression 
Table 3 — Effect of chrysin on mRNA expression of β-MHC and TGF-β in heart of control and L-NAME induced hypertensive rats 
 Control Control+25 mg chysin L-NAME induced hypertension L-NAME+25 mg chrysin 
β-MHC (Relative fold 
changes) 
1.02 ± 0.05 a 1.02 ± 0.04 a 5.27 ± 0.07 b 1.05 ± 0.05 c 
TGF-β (Relative fold 
changes) 
1.03 ± 0.09a 1.02 ± 0.08 a 5.99 ± 0.41 b 1.09 ± 0.07c 
Each value is mean ± S.D. for six rats in each group. 
Values not sharing a common superscripts (a, b and c) differ significantly at P < 0.05 (DMRT). 
 
 
Fig. 2 — eNOS mRNA expression in aorta, heart, and kidney of 
the groups. Columns are mean ± SD of six rats from each group. 
Columns not sharing a common superscripts (a, b and c) differ 
significantly at P < 0.05 (DMRT) 




of eNOS might in turn have led to an increase in eNOS 
activity and NO production. Moreover, it is thought 
that this increase in the expression of eNOS might 
elicit the anti-inflammatory and antiatherosclerotic 
effects of a chrysin in the L-NAME- treated rat aorta. It 
should be noted this putative mechanism is also indicated 
by evidence demonstrating that chrysin improves 
endothelial dysfunction by increasing NO production in 
the hypertensive rat aorta, heart, and kidney. 
At the molecular level, pathological stresses induce 
multiple changes, including genetic reprogramming 
(the re-expression of a battery of fetal genes and the 
down regulation of multiple adult genes). Together, 
these changes in gene expression result in substantial 
phenotypic changes, including changes in size, 
contractility, metabolic state, and electric conductance
27
. 
The up-regulated gene TGF-β is a locally generated 
cytokine that has been implicated as a major contributor 
to tissue fibrosis and the latest studies in humans and 
experimental models have shown increased myocardial 
TGF-β expression during cardiac hypertrophy and 
fibrosis
28
. Moreover, cardiac oxidative stress promotes 
the development of cardiac fibrosis by up-regulating 
TGF-β expression, which subsequently enhances cardiac 
collagen synthesis and suppresses collagen degradation 
in hypertensive rats
29
. In the pressure-overloaded human 
heart, the up-regulation of ACE and TGF-β correlated 
with the degree of fibrosis
30
. A recent study 
investigated the intracellular signalling events that are 
required for Ang II-dependent up-regulation of TGF-β 
revealed that the induction of TGF-β mRNA by Ang 
II in adult ventricular cardiomyocytes is mediated by 
NAD(P)H oxidase
31
. This indicates the possible role of 
oxidative stress in the TGF-β-Ang II (ACE) circuit  
and hypertrophy. In this study, the intervention of  
this circuit by chrysin (antioxidant role) at the level of 
oxidative stress and ACE prevents fibrosis and cardiac 
remodeling. 
Pathological hypertrophy is characterized by increase 
in cardiomyocyte diameter, oxidative stress, fibrosis, and 
expression of β-MHC (a fetal specific isoform)
32
.  
The up-regulation of β-MHC transcription has been used 
as an early and sensitive marker of cardiac hypertrophy.  
In general, α-MHC is normally a predominant isoform 
occurring in the heart and expression of β-MHC 
contributes to the overall poor functioning of the 
hypertrophic ventricle
33
. A previous study indicated that, 
oxidative stress induced by chronic hyperglycemia 
increased the activation of the pleiotropic transcription 
factor nuclear factor-κB (NF-κB). NF-κB activation 
triggered a cascade of signalling, which finally led to 
the switch in the cardiac MHC gene expression from 
the α-MHC isoform to the β-MHC isoform
34
. Thus, the 
effect of chrysin on reduced expression of β-MHC 
isoform might be due to its preventive effect on 
oxidative stress which in turn suppresses the cardiac 
remodeling in L-NAME rats.  
 
Conclusion 
Our result explored that, oral administration of chrysin 
(25 mg/kg BWT) significantly decreased the expression 
of β-MHC and TGF-β and attenuated eNOS mRNA 
expression in L-NAME induced hypertensive rats. Thus, 
chrysin analogs might be potential therapeutic agents for 
treating L-NAME induced hypertension. 
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